Drug delivery to brain tumors

Current Neurology and Neuroscience Reports

Volumn 8, Issue 3, 2008, Pages 235-241

  Blakeley, Jaishri ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; ABC TRANSPORTER; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOSTEROID DERIVATIVE; CYTOCHROME P450; CYTOTOXIC AGENT; DIPHTHERIA TOXIN; ETOPOSIDE; GADOLINIUM TEXAPHYRIN; GLYCOPROTEIN P INHIBITOR; INSULIN; INTERLEUKIN 13; IODINE 131; LIPOSOME; METHOTREXATE; NANOPARTICLE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; POLYMER; TEMOZOLOMIDE; TRANSFERRIN;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN HYPOXIA; BRAIN TUMOR; CATHETER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; EDEMA; HUMAN; LIQUORRHEA; NANOENCAPSULATION; NANOENGINEERING; NONHUMAN; PRESSURE GRADIENT; REVIEW; WOUND HEALING IMPAIRMENT; ANIMAL; DRUG ADMINISTRATION ROUTE; DRUG EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 49649121238     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-008-0036-8     Document Type: Review

References (50)

1. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23:2445-2459.
2. Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007, 6:1909-1919.
3. Deeken JF, Loscher W: The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 2007, 13:1663-1674.
4. Colgan OC, Collins NT, Ferguson G, et al.: Influence of basolateral condition on the regulation of brain micro-vascular endothelial tight junction properties and barrier function. Brain Res 2008, 1193:84-92.
5. Calatozzolo C, Gelati M, Ciusani E, et al.: Expression of drug resistance proteins pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005, 74:113-121.
6. Szabo D, Keyzer H, Kaiser HE, Molnar J: Reversal of multidrug resistance of tumor cells. Anticancer Res 2000, 20:4261-4274.
7. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM: Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007, 24:1720-1728.
8. de Vries NA, Zhao J, Kroon E, et al.: P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007, 13:6440-6449.
9. Szakacs G, Paterson JK, Ludwig JA, et al.: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
10. Grossman SA, Hochberg F, Fisher J, et al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 1998, 42:118-126.
11. Jones AR, Shusta EV: Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007, 24:1759-1771.
12. Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000, 2:45-59.
13. Xia CF, Zhang Y, Zhang Y, et al.: Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007, 24:2309-2316.
14. Lu W, Zhang Y, Tan YZ, et al.: Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005, 107:428-448.
15. Muldoon LL, Soussain C, Jahnke K, et al.: Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25:2295-2305.
16. Mohile NA, Abrey LE: Primary central nervous system lymphoma. Neurol Clin 2007, 25:1193-1207.
17. Vinolas N, Gil M, Verger E, et al.: Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs 2002, 13:163-167.
18. Dropcho EJ, Rosenfeld SS, Vitek J, et al.: Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998, 36:191-198.
19. Ashby LS, Shapiro WR: Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 2001, 51:67-86.
20. Fortin D, Desjardins A, Benko A, et al.: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005, 103:2606-2615.
21. Remsen LG, Trail PA, Hellstrom I, et al.: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000, 46:704-709.
22. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA: Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001, 48:1033-1040; discussion 1040-1041.
23. Jahnke K, Kraemer DF, Knight KR, et al.: Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 2008, 112:581-588.
24. Cao Y, Tsien CI, Shen Z, et al.: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005, 23:4127-4136.
25. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? [review]. Oncol Rep 2002, 9:683-688.
26. Ma J, Pulfer S, Li S, et al.: Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001, 61:5491-5498.
27. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
28. Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995, 345:1008-1012.
29. Westphal M, Hilt DC, Bortey E, et al.: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, 5:79-88.
30. Fung LK, Ewend MG, Sills A, et al.: Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998, 58:672-684.
31. Weingart J, Grossman SA, Carson KA, et al,: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007, 25:399-404.
32. Olivi A, Grossman SA, Tatter S, et al.; New Approaches to Brain Tumor Therapy CNS Consortium: Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 2003, 21:1845-1849.
33. Ewend MG, Brem S, Gilbert M, et al.: Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007, 13:3637-3641.
34. Vukelja SJ, Anthony SP, Arseneau JC, et al.: Phase 1 study of escalating-dose OncoGel (ReGel/pactitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007, 18:283-289.
35. Sheleg SV, Korotkevich EA, Zhavrid EA, et al.: Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002, 60:53-59.
36. Patel SJ, Shapiro WR, Laske DW, et al.: Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, 56:1243-1252; discussion 1252-1253.
37. Kunwar S, Prados MD, Chang SM, et al.: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the cintredekin besudotox intraparenchymal study group. J Clin Oncol 2007, 25:837-844.
38. Grossman SA, Trump DL, Chen DC, et al.: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982, 73:641-647.
39. Mamelak AN, Rosenfeld S, Bucholz R, et al.: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006, 24:3644-3650.
40. Reddy GR, Bhojani MS, McConville P, et al.: Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12:6677-6686.
41. Yoshida J, Mizuno M: Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J Neurooncol 2003, 65:261-267.
42. Shao K, Hou Q, Duan W, et al.: Intracellular drug delivery by sulfatide-mediated tiposomes to gliomas. J Control Release 2006, 115:150-157.
43. de Lange EC, de Vries JD, Zurcher C, et al.: The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 1995, 12:1924-1931.
44. Olson J, Blakeley J, Grossman SA, et al.: Differences in the distribution of methotrexate into high grade gliomas following intravenous administration, as monitored by microdialysis, are associated with blood brain barrier integrity [abstract]. J Clin Oncol 2006, 24:1548.
45. Portnow J, Badie B, Xi B, et al.: Intracerebral microdialysis for determination of the neuropharmacokinetics and neuropharmacodynamics of temozolomide in patients with primary or metastatic brain tumors [abstract]. J Clin Oncol 2007, 25:2074.
46. Bergenheim AT, Roslin M, Ungerstedt U, et al.: Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of L-2, 4 diaminobutyric acid (DAB). J Neurooncol 2006, 80:285-293.
47. Mishani E, Abourbeh G: Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007, 7:1755-1772.
48. Sharma V, Prior JL, Belinsky MG, et al.: Characterization of a 67Ga/ 68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 2005, 46:354-364.
49. Wu GN, Ford JM, Alger JR: MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 2006, 77:95-103.
50. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.